Patents by Inventor Michael W. Heartlein
Michael W. Heartlein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20030147868Abstract: The present invention relates to transfected primary, secondary, and immortalized cells of vertebrate origin particularly mammalian origin, transfected with exogenous genetic material (DNA) which encodes a desired (e.g., a therapeutic) product or is itself a desired (e.g., therapeutic) product, methods by which primary, secondary and immortalized cells are transfected to include exogenous genetic material, including DNA targeting by homologous recombination, methods for the activation and amplification of endogenous cellular genes, methods by which cells useful for large-scale protein production can be obtained, methods of producing clonal cell strains or heterogenous cell strains, and methods of gene therapy in which transfected primary, secondary or immortalized cells are used.Type: ApplicationFiled: November 18, 2002Publication date: August 7, 2003Applicant: Transkaryotic Therapies, Inc. a Delaware corporationInventors: Douglas Treco, Michael W. Heartlein, Richard F. Selden
-
Patent number: 6565844Abstract: The present invention relates to DNA constructs that alter the expression of a targeted gene in a cell when the DNA construct is homologously recombined with a target site within the chromosomal DNA of the cell, as well as to a cell into which has been incorporated a new transcription unit containing an exogenous regulatory sequence operatively linked to an endogenous gene of the cell's chromosomal DNA. These constructs and cells can be used in a method of altering expression of the targeted gene.Type: GrantFiled: May 14, 1999Date of Patent: May 20, 2003Assignee: Transkaryotic Therapies, Inc.Inventors: Douglas Treco, Michael W. Heartlein, Richard F Selden
-
Publication number: 20030082675Abstract: The invention relates to novel human DNA sequences, targeting constructs, and methods for producing novel genes encoding thrombopoietin, DNase I, and &bgr;-interferon by homologous recombination. The targeting constructs comprise at least: a) a targeting sequence; b) a regulatory sequence; c) an exon; and d) a splice-donor site. The targeting constructs, which can undergo homologous recombination with endogenous cellular sequences to generate a novel gene, are introduced into cells to produce homologously recombinant cells. The homologously recombinant cells are then maintained under conditions which will permit transcription of the novel gene and translation of the mRNA produced, resulting in production of either thrombopoietin, DNase I, or &bgr;-interferon.Type: ApplicationFiled: January 6, 1999Publication date: May 1, 2003Inventors: DOUGLAS A. TRECO, MICHAEL W. HEARTLEIN, BRIAN M. HAUGE, RICHARD F. SELDON
-
Patent number: 6537542Abstract: The present invention relates to a method of gene or DNA targeting in cells of vertebrate, particularly mammalian, origin. That is, it relates to a method of introducing DNA into primary or secondary cells of vertebrate origin through homologous recombination or targeting of the DNA, which is introduced into genomic DNA of the primary or secondary cells at a preselected site. The present invention further relates to primary or secondary cells, referred to as homologously recombinant (HR) primary or secondary cells, produced by the present method and to uses of the homologously recombinant primary or secondary cells. The present invention also relates to a method of turning on a gene present in primary cells, secondary cells or immortalized cells of vertebrate origin, which is normally not expressed in the cells or is not expressed at significant levels in the cells.Type: GrantFiled: April 14, 2000Date of Patent: March 25, 2003Assignee: Transkaryotic Therapies, Inc.Inventors: Douglas Treco, Michael W. Heartlein, Richard F Selden
-
Patent number: 6531124Abstract: The present invention relates to transfected primary and secondary somatic cells of vertebrate origin, particularly mammalian origin, transfected with exogenous genetic material (DNA) that encodes erythropoietin or an insulinotropin (e.g., derivatives of glucagon-like peptide 1 (GLP 1)), methods by which primary and secondary cells are transfected to include exogenous genetic material encoding erythropoietin or an insulinotropin, methods of producing clonal cell strains or heterogenous cell strains that express erythropoietin or an insulinotropin, methods of gene therapy, in which the transfected primary or secondary cells are used, and methods of producing antibodies using the transfected primary or secondary cells.Type: GrantFiled: August 16, 1999Date of Patent: March 11, 2003Assignee: Transkaryotic Therapies, Inc.Inventors: Richard F Selden, Douglas Treco, Michael W. Heartlein
-
Publication number: 20030022850Abstract: An isolated nucleic acid molecule that hybridizes under stringent conditions, or shares at least 80% sequence identity, with a defined genomic region upstream of the coding region of the G-CSF gene, and a DNA construct containing that DNA molecule as a targeting sequence for homologous recombination.Type: ApplicationFiled: April 27, 2001Publication date: January 30, 2003Inventors: Douglas A. Treco, Michael W. Heartlein, Richard F. Selden
-
Publication number: 20020155597Abstract: The present invention relates to transfected primary and secondary somatic cells of vertebrate origin, particularly mammalian origin, transfected with exogenous genetic material (DNA) which encodes erythropoietin or an insulinotropin [e.g., derivatives of glucagon-like peptide 1 (GLP-1)], methods by which primary and secondary cells are transfected to include exogenous genetic material encoding erythropoietin or an insulinotropin, methods of producing clonal cell strains or heterogenous cell strains which express eruthropoietin or an insulinotropin, methods of gene therapy in which the transfected primary or secondary cells are used, and methods of producing antibodies using the transfected primary or secondary cells.Type: ApplicationFiled: June 8, 1999Publication date: October 24, 2002Inventors: RICHARD F SELDEN, DOUGLAS TRECO, MICHAEL W. HEARTLEIN
-
Patent number: 6355241Abstract: The present invention relates to transfected primary and secondary somatic cells of vertebrate origin, particularly mammalian origin, transfected with exogenous genetic material (DNA) which encodes erythropoietin or an insulinotropin [e.g., derivatives of glucagon-like peptide 1(GLP-1)], methods by which primary and secondary cells are transfected to include exogenous genetic material encoding erythropoietin or an insulinotropin, methods of producing clonal cell strains or heterogenous cell strains which express eruthropoietin or an insulinotropin, methods of gene therapy in which the transfected primary or secondary cells are used, and methods of producing antibodies using the transfected primary or secondary cells.Type: GrantFiled: October 19, 1999Date of Patent: March 12, 2002Assignee: Transkaryotic Therapies, Inc.Inventors: Richard F Selden, Douglas Treco, Michael W. Heartlein
-
Publication number: 20010034044Abstract: An isolated nucleic acid molecule that hybridizes under stringent conditions, or shares at least 80% sequence identity, with a defined genomic region upstream of the coding region of a FSH&bgr; gene, and a DNA construct containing that nucleic acid molecule as a targeting sequence for homologous recombination.Type: ApplicationFiled: March 8, 2001Publication date: October 25, 2001Inventors: Douglas A. Treco, Michael W. Heartlein, Richard F. Selden
-
Patent number: 6303379Abstract: The present invention relates to transfected primary and secondary somatic cells of vertebrate origin, particularly mammalian origin, transfected with exogenous genetic material (DNA) which encodes a desired (e.g., a therapeutic) product or is itself a desired (e.g., therapeutic) product, methods by which primary and secondary cells are transfected to include exogenous genetic material, methods of producing clonal cell strains or heterogenous cell strains, methods of gene therapy in which the transfected primary or secondary cells are used, and methods of producing antibodies using the transfected primary or secondary cells.Type: GrantFiled: July 16, 1999Date of Patent: October 16, 2001Assignee: Transkaryotic Therapies, Inc.Inventors: Richard F Selden, Douglas Treco, Michael W. Heartlein
-
Publication number: 20010025026Abstract: Chimeric proteins useful in transporting a selected substance present in extracellular fluids, such as blood or lymph, into cells; quantitative assays for the selected substance using chimeric proteins; DNA encoding the chimeric proteins; plasmids which contain DNA encoding the chimeric proteins; mammalian cells, modified to contain DNA encoding the chimeric proteins, which express and, optionally, secrete the chimeric proteins; a method of producing the chimeric proteins; a method of isolating the chimeric proteins; a method of using the chimeric proteins to assay the selected substance; and a method of reducing extracellular levels of the selected substance through administration of the chimeric protein, which results in transport of the selected substance into cells.Type: ApplicationFiled: January 3, 2001Publication date: September 27, 2001Applicant: Transkaryotic Therapies, Inc. Delaware CorporationInventors: Michael W. Heartlein, Jeffrey F. Lemontt, Michael F. Concino
-
Patent number: 6270989Abstract: The invention relates to novel human DNA sequences, targeting constructs, and methods for producing novel genes encoding thrombopoietin, DNase I, and &bgr;-interferon by homologous recombination. The targeting constructs comprise at least: a) a targeting sequence; b) a regulatory sequence; c) an exon; and d) a splice-donor site. The targeting constructs, which can undergo homologous recombination with endogenous cellular sequences to generate a novel gene, are introduced into cells to produce homologously recombinant cells. The homologously recombinant cells are then maintained under conditions which will permit transcription of the novel gene and translation of the mRNA produced, resulting in production of either thrombopoietin, DNase I, or &bgr;-interferon.Type: GrantFiled: March 17, 1995Date of Patent: August 7, 2001Assignee: Transkaryotic Therapies, Inc.Inventors: Douglas A. Treco, Michael W. Heartlein, Brian M. Hauge, Richard F Selden
-
Patent number: 6262026Abstract: Chimeric proteins which comprise a ligand-binding domain of a first receptor and a carrier domain which tends a cell surface receptor other than the first receptor, useful in transporting a selected substance present in extracellular fluids, such as blood or lymph, into cells; quantitative assays for the selected substance using chimeric proteins; DNA encoding the chimeric proteins; plasmids which contain DNA encoding the chimeric proteins; mammalian cells, modified to contain DNA encoding the chimeric proteins, which express and, optionally, secrete the chimeric proteins; a method of producing the chimeric proteins; a method of isolating the chimeric proteins; a method of using the chimeric proteins to assay the selected substance; and a method of reducing extracellular levels of the selected substance through administration of the chimeric protein, which results in transport of the selected substance into cells.Type: GrantFiled: April 2, 1999Date of Patent: July 17, 2001Assignee: Transkaryotic Therapies, Inc.Inventors: Michael W. Heartlein, Jeffrey F. Lemontt, Michael F. Concino
-
Patent number: 6242218Abstract: An isolated nucleic acid molecule that hybridizes under stringent conditions, or shares at least 80% sequence identity, with a defined genomic region upstream of the coding region of the G-CSF gene, and a DNA construct containing that DNA molecule as a targeting sequence for homologous recombination.Type: GrantFiled: May 5, 1999Date of Patent: June 5, 2001Assignee: Transkaryotic Therapies Inc.Inventors: Douglas A. Treco, Michael W. Heartlein, Richard F Selden
-
Patent number: 6214622Abstract: The present invention relates to a method of gene or DNA targeting in cells of vertebrate, particularly mammalian, origin. That is, it relates to a method of introducing DNA into primary or secondary cells of vertebrate origin through homologous recombination or targeting of the DNA, which is introduced into genomic DNA of the primary or secondary cells at a preselected site. The present invention further relates to primary or secondary cells, referred to as homologously recombinant (HR) primary or secondary cells, produced by the present method and to uses of the homologously recombinant primary or secondary cells. The present invention also relates to a method of turning on a gene present in primary cells, secondary cells or immortalized cells of vertebrate origin, which is normally not expressed in the cells or is not expressed at significant levels in the cells.Type: GrantFiled: May 18, 1995Date of Patent: April 10, 2001Assignee: Transkaryotic Therapies, Inc.Inventors: Douglas Treco, Michael W. Heartlein, Richard F Selden
-
Patent number: 6200778Abstract: An isolated nucleic acid molecule that hybridizes under stringent conditions, or shares at least 80% sequence identity, with a defined genomic region upstream of the coding region of a FSH&bgr; gene, and a DNA construct containing that nucleic acid molecule as a targeting sequence for homologous recombination.Type: GrantFiled: May 5, 1999Date of Patent: March 13, 2001Assignee: Transkaryotic Therapies, Inc.Inventors: Douglas A. Treco, Michael W. Heartlein, Richard F Selden
-
Patent number: 6187305Abstract: The present invention relates to a method of gene or DNA targeting in cells of vertebrate, particularly mammalian, origin. That is, it relates to a method of introducing DNA into primary or secondary cells of vertebrate origin through homologous recombination or targeting of the DNA, which is introduced into genomic DNA of the primary or secondary cells at a preselected site. The present invention further relates to primary or secondary cells, referred to as homologously recombinant (HR) primary or secondary cells, produced by the present method and to uses of the homologously recombinant primary or secondary cells. The present invention also relates to a method of turning on a gene present in primary cells, secondary cells or immortalized cells of vertebrate origin, which is normally not expressed in the cells or is not expressed at significant levels in the cells.Type: GrantFiled: May 18, 1995Date of Patent: February 13, 2001Assignee: Transkaryotic Therapies, Inc.Inventors: Douglas Treco, Michael W. Heartlein, Richard F Selden
-
Patent number: 6063630Abstract: The present invention relates to a method of gene or DNA targeting in cells of vertebrate, particularly mammalian, origin. That is, it relates to a method of introducing DNA into primary or secondary cells of vertebrate origin through homologous recombination or targeting of the DNA, which is introduced into genomic DNA of the primary or secondary cells at a preselected site. The present invention further relates to primary or secondary cells, referred to as homologously recombinant (HR) primary or secondary cells, produced by the present method and to uses of the homologously recombinant primary or secondary cells. The present invention also relates to a method of turning on a gene present in primary cells, secondary cells or immortalized cells of vertebrate origin, which is normally not expressed in the cells or is not expressed at significant levels in the cells.Type: GrantFiled: April 20, 1994Date of Patent: May 16, 2000Assignee: Transkaryotic Therapies, Inc.Inventors: Douglas Treco, Michael W. Heartlein, Richard F Selden
-
Patent number: 6054288Abstract: The present invention relates to transfected primary and secondary somatic cells of vertebrate origin, particularly mammalian origin, transfected with exogenous genetic material (DNA) which encodes a desired (e.g., a therapeutic) product or is itself a desired (e.g., therapeutic) product, methods by which primary and secondary cells are transfected to include exogenous genetic material, methods of producing clonal cell strains or heterogenous cell strains, methods of gene therapy in which the transfected primary or secondary cells are used, and methods of producing antibodies using the transfected primary or secondary cells.Type: GrantFiled: May 18, 1995Date of Patent: April 25, 2000Assignee: Transkaryotic Therapies, Inc.Inventors: Richard F Selden, Douglas Treco, Michael W. Heartlein
-
Patent number: 6048524Abstract: The present invention relates to transfected primary and secondary somatic cells of vertebrate origin, particularly mammalian origin, transfected with exogenous genetic material (DNA) which encodes erythropoietin or an insulinotropin [e.g., derivatives of glucagon-like peptide 1(GLP-1)], methods by which primary and secondary cells are transfected to include exogenous genetic material encoding erythropoietin or an insulinotropin, methods of producing clonal cell strains or heterogenous cell strains which express eruthropoietin or an insulinotropin, methods of gene therapy in which the transfected primary or secondary cells are used, the methods of producing antibodies using the transfected primary or secondary cells.Type: GrantFiled: May 22, 1995Date of Patent: April 11, 2000Assignee: Transkaryotic Therapies, Inc.Inventors: Richard F Selden, Douglas Treco, Michael W. Heartlein